Your browser doesn't support javascript.
loading
How Should We Assign Large Infiltrative Hepatocellular Carcinomas for Staging?
Lee, Yoo Jin; Lee, Yoo Ra; Seo, Chung Gyo; Goh, Hyun Gil; Kim, Tae Hyung; Yim, Sun Young; Han, Na Yeon; Lee, Jae Min; Choi, Hyuk Soon; Kim, Eun Sun; Keum, Bora; An, Hyonggin; Park, Beomjin; Seo, Yeon Seok; Yim, Hyung Joon; Kim, Ji Hoon; Yu, Young Dong; Kim, Dong Sik; Jeen, Yoon Tae; Chun, Hoon Jai; Lee, Hong Sik; Kim, Chang Duck; Um, Soon Ho.
Affiliation
  • Lee YJ; Department of Pathology, Korea University Medical Center, Seoul 136-701, Korea.
  • Lee YR; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Medical Center, Seoul 136-701, Korea.
  • Seo CG; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Medical Center, Seoul 136-701, Korea.
  • Goh HG; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Medical Center, Seoul 136-701, Korea.
  • Kim TH; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Medical Center, Seoul 136-701, Korea.
  • Yim SY; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Medical Center, Seoul 136-701, Korea.
  • Han NY; Department of Radiology, Korea University Medical Center, Seoul 136-701, Korea.
  • Lee JM; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Medical Center, Seoul 136-701, Korea.
  • Choi HS; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Medical Center, Seoul 136-701, Korea.
  • Kim ES; Department of Pathology, Korea University Medical Center, Seoul 136-701, Korea.
  • Keum B; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Medical Center, Seoul 136-701, Korea.
  • An H; Department of Biostatistics, Korea University Medical Center, Seoul 136-701, Korea.
  • Park B; Department of Radiology, Korea University Medical Center, Seoul 136-701, Korea.
  • Seo YS; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Medical Center, Seoul 136-701, Korea.
  • Yim HJ; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Medical Center, Seoul 136-701, Korea.
  • Kim JH; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Medical Center, Seoul 136-701, Korea.
  • Yu YD; Department of Surgery, Korea University Medical Center, Seoul 136-701, Korea.
  • Kim DS; Department of Surgery, Korea University Medical Center, Seoul 136-701, Korea.
  • Jeen YT; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Medical Center, Seoul 136-701, Korea.
  • Chun HJ; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Medical Center, Seoul 136-701, Korea.
  • Lee HS; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Medical Center, Seoul 136-701, Korea.
  • Kim CD; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Medical Center, Seoul 136-701, Korea.
  • Um SH; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Medical Center, Seoul 136-701, Korea.
Cancers (Basel) ; 12(9)2020 Sep 10.
Article in En | MEDLINE | ID: mdl-32927918
ABSTRACT
Infiltrative gross morphology of hepatocellular carcinoma (HCC) is known to be associated with poor prognosis, but this is not considered for staging. A total of 774 HCC patients who underwent curative liver resection were retrospectively reviewed and the prognostic significance of infiltrative type HCC was assessed using the American Joint Committee on Cancer (AJCC) and Barcelona Clinic Liver Cancer (BCLC) staging systems. Seventy-four patients (9.6%) had infiltrative HCCs with a higher proportion of multifocal tumors, larger tumors, vessel invasion, increased tumor marker levels, and advanced T-stages than those with nodular HCC (all, p < 0.01). Infiltrative morphology was independently associated with lower overall survival (OS), but its impact was significant when the tumor size was ≥ 4 cm (p < 0.001). Under current AJCC and BCLC staging criteria, these large infiltrative HCCs were associated with significantly worse OS in early AJCC T-stages (T1b/T2, p < 0.001) and BCLC stage A/B (both, p < 0.01) but not in late AJCC (T3/T4) and BCLC C. The reassignment of this subtype to T3 and T4 increased the discriminatory ability of AJCC T-staging with lower AIC values (3090 and 3088 vs. 3109) and higher c-index (0.69 and 0.69 vs. 0.67), respectively (both, p < 0.001). Similarly, the reassignment of large infiltrative HCC to BCLC stages B and C also improved the prognostic performance. Large infiltrative HCCs should be assigned to more advanced stages in current staging systems for their prognostic impact.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Cancers (Basel) Year: 2020 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Cancers (Basel) Year: 2020 Document type: Article